Breakpoints
The SIDP Podcast

#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID

In this special LIVE podcast episode, Drs. Emily Heil (@emilylheil) and Erin McCreary (@Erin McCreary) sit down at MAD-ID 2022 (@MAD_ID_ASP) and give a rundown of 36 of some of the best ID papers, abstracts, studies, and other cool stuff from 2021 and early 2022! They cover everything from ECCMID late breakers to gram-negative RCTs to stewardship to fungi (but NOT COVID-19). Listen now!

Handout: https://drive.google.com/file/d/1OdYP9WpNGFmslw_G_vTPYF0cJZoxN8jo/view

LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx

References PMIDs

  1. IMPRESU: 34620666
  2. TARGET: 35106617
  3. MERINO-2: 34395716
  4. Tazobactam SIDP Insight: 34689349
  5. TMP-SMX vs FQ for Steno: 35097154
  6. Elexacaftor-Tezacaftor-Ivacaftor: 35142340
  7. Antibiotic Inertia: 34596206
  8. Antibiotic Overuse at Discharge: 34554249
  9. Pharmacist-Driven TOC: 35536577
  10. Tele-stewardship: 34141816
  11. MRSA Surveillance Culture: 29340593
  12. MRSA Screen Durability: 33788910
  13. Antifungal Pipeline: 34626339
  14. Antifungal Susceptibility Testing: 347784889
  15. Posa vs Vori for Aspergillosis: 33549194
  16. AMBITION: 35320642
  17. FLAGSTONE: 35085510
  18. SOLSTICE: 34864943
  19. Probiotics for Primary Prevention: 33972996
  20. Probiotics and VAP: 34546300
  21. SER-109: 35045228
  22. Bayesian vs First-Order Vanc AUC: 35134264
  23. Beta-lactam Admin Order: 34606585
  24. Candida Endophthalmitis: 34293405
  25. FUO Review: 35108471
  26. 7 vs 14 Days for Male UTI: 34313686

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#59 – Resistance in Pseudomonas aeruginosa: Pearls and Perils

Drs. Antonio Oliver (@aoliverp73) and Maggie Monogue (@MaggieMonogue) join Dr. Erin McCreary (@Erin McCreary) to discuss all things Pseudomonas aeruginosa. Tune in to learn from some of the best about the complexities of P. aeruginosa resistance, the role of various antibiotics in the management of DTR isolates, and much more!

LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx

References Shields RK, et al. Clin Infect Dis. 2022;ciac097. doi: 10.1093/cid/ciac097.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#58 – We're Gonorrhea-valuate: Updates and Implementation of STI Treatment Guidelines

Drs. Brian Werth (@bdubrx), Zack Nelson (@zacroBID) and Amy Brotherton (@AmyBrother10) join Dr. Jillian Hayes (@thejillianhayes) to discuss updates in the management of sexually transmitted infections. Listen in for guidance on how doses are selected, practical implementation of guideline changes, and how to discuss these changes with patients.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

  1. St. Cyr S, et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1911–1916. doi: http://dx.doi.org/10.15585/mmwr.mm6950a6
  2. STI treatment guidelines. Centers for Disease Control and Prevention. https://www.cdc.gov/std/treatment-guidelines/default.htm. Published 2021. Accessed May 12, 2022. 
  3. National overview – sexually transmitted Disease SURVEILLANCE, 2019. Centers for Disease Control and Prevention. https://www.cdc.gov/std/statistics/2019/overview.htm. Published April 13, 2021. Accessed May 12, 2022.
  4. Doan T, et al. N Engl J Med. 2020 Nov 12;383(20):1941-1950. doi: 10.1056/NEJMoa2002606. PMID: 33176084. 
  5. Doan T, et al. N Engl J Med. 2019 Jun 6;380(23):2271-2273. doi: 10.1056/NEJMc1901535. PMID: 33167060.
  6. Kong FYS, et al. Clin Infect Dis. 2014 Jul 15;59(2):193-205. doi: 10.1093/cid/ciu220. PMID: 24729507. 
  7. Dombrowski JC, et al. Clin Infect Dis. 2021 Sep 7;73(5):842-831. doi: 10.1093/cid/ciab153. PMID: 33606009. 
  8. Connolly KL, et al. Antimicrob Agents Chemother. 2019 Feb 26;63(3):e01644-18. doi: 10.1128/AAC.01644-18. PMID: 30642924. 
  9. Páez-Canro C, et al. Cochrane Database Syst Rev. 2019 Jan 25;1(1):CD010871. doi: 10.1002/14651858.CD010871.pub2. PMID: 30682211. 
  10. Dukeres-Muijrers NHTM, et al. Sex Transm Infect. 2021 Mar;97(2):147-151. doi: 10.1136/sextrans-2020-054558. Epub 2020 Jul 31. PMID: 32737209.
  11. Manavi K, et al. Int J STD AIDS. 2016 Dec;27(14):1303-1308. doi: 10.1177/0956462415614723. Epub 2015 Oct 27. PMID: 26511655. 
  12. Chisholm SA, et al. J Antimicrob Chemother. 2010 Oct;65(10):2141-8. doi: 10.1093/jac/dkq289. Epub 2010 Aug 6. PMID: 20693173. 
  13. Kastner U, et al. Infection. 2001 Oct;29(5):251-6. doi: 10.1007/s15010-001-1072-3. PMID: 11688901.
  14. Dellamonica P. J Antimicrob Chemother. 2002 Oct;50(4):614-5. doi: 10.1093/jac/dkf166. PMID: 12356813.
  15. Davidson RJ. Infect Drug Resist. 2019 Mar 8;12:585-596. doi: 10.2147/IDR.S187226. PMID: 30881064.
  16. Burr LD, et al. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0224621. doi: 10.1128/aac.02246-21. PMID: 35293783.
  17. Hepatitis C State of Medicaid Access: https://stateofhepc.org

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#57 – Dosing Consult: Ceftriaxone

Drs. Tom Dilworth and Stephanie Shealy May (@stephshealymay) join Dr. Rachel Britt (@RachelBPharmD) in the first episode of Breakpoints Dosing Consults to discuss questions and debates around ceftriaxone dosing. When should we use 1g over 2g? How does critical illness affect what dose to use? Is ceftriaxone the most approachable antibiotic? Tune in for answers to these questions and more!  

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

  1. Ettestad PJ, Campbell GL, Welbel SF, Genese CA, Spitalny KC, Marchetti CM, Dennis DT. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis. 1995 Feb;171(2):356-61. doi: 10.1093/infdis/171.2.356. PMID: 7844372.
  2. Hasegawa S, Sada R, Yaegashi M, Morimoto K, Mori T; Adult Pneumonia Study Group-Japan. 1g versus 2 g daily intravenous ceftriaxone in the treatment of community onset pneumonia - a propensity score analysis of data from a Japanese multicenter registry. BMC Infect Dis. 2019 Dec 26;19(1):1079. doi: 10.1186/s12879-019-4552-8. PMID: 31878894; PMCID: PMC6933656.
  3. Barber KE, Loper JT, Morrison AR, Stover KR, Wagner JL. Impact of Obesity on Ceftriaxone Efficacy. Diseases. 2020 Jul 9;8(3):27. doi: 10.3390/diseases8030027. PMID: 32660113; PMCID: PMC7563366.
  4. Herrera-Hidalgo L, de Alarcón A, López-Cortes LE, Luque-Márquez R, López-Cortes LF, Gutiérrez-Valencia A, Gil-Navarro MV. Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs? Antimicrob Agents Chemother. 2020 Dec 16;65(1):e02099-20. doi: 10.1128/AAC.02099-20. Erratum in: Antimicrob Agents Chemother. 2021 May 18;65(6): PMID: 33046488; PMCID: PMC7927845.
  5. Herrera-Hidalgo L, Lomas-Cabezas JM, López-Cortés LE, Luque-Márquez R, López-Cortés LF, Martínez-Marcos FJ, de la Torre-Lima J, Plata-Ciézar A, Hidalgo-Tenorio C, García-López MV, Vinuesa D, Gutiérrez-Valencia A, Gil-Navarro MV, De Alarcón A. Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT. J Clin Med. 2021 Dec 21;11(1):7. doi: 10.3390/jcm11010007. PMID: 35011748; PMCID: PMC8745305.
  6. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1. PMID: 34292926; PMCID: PMC8344968.
  7. Whittles LK, White PJ, Paul J, Didelot X. Epidemiological Trends of Antibiotic Resistant Gonorrhoea in the United Kingdom. Antibiotics (Basel). 2018 Jul 13;7(3):60. doi: 10.3390/antibiotics7030060. PMID: 30011825; PMCID: PMC6165062.
  8. Ackerman A, Zook NR, Siegrist JF, Brummitt CF, Cook MM, Dilworth TJ. Comparison of Clinical Outcomes among Intensive Care Unit Patients Receiving One or Two Grams of Ceftriaxone Daily. Antimicrob Agents Chemother. 2020 May 21;64(6):e00066-20. doi: 10.1128/AAC.00066-20. PMID: 32205348; PMCID: PMC7269488.
  9. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99-110. doi: 10.2165/11539220-000000000-00000. PMID: 21142293.
  10. Dailly E, Arnould JF, Fraissinet F, Naux E, Letard de la Bouralière MA, Bouquié R, Deslandes G, Jolliet P, Le Floch R. Pharmacokinetics of ertapenem in burns patients. Int J Antimicrob Agents. 2013 Jul;42(1):48-52. doi: 10.1016/j.ijantimicag.2013.02.021. Epub 2013 Apr 8. PMID: 23578794.
  11. Pai MP. Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage. Curr Opin Pharmacol. 2015 Oct;24:12-7. doi: 10.1016/j.coph.2015.06.004. Epub 2015 Jun 25. PMID: 26119488.
  12. Mahmood I. Theoretical versus empirical allometry: Facts behind theories and application to pharmacokinetics. J Pharm Sci. 2010 Jul;99(7):2927-33. doi: 10.1002/jps.22073. PMID: 20127826.
  13. Kang N, Housman ST, Nicolau DP. Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures. Pathogens. 2015 Jul 30;4(3):599-605. doi: 10.3390/pathogens4030599. PMID: 26264030; PMCID: PMC4584275.
  14. Gern BH, Greninger AL, Weissman SJ, Stapp JR, Tao Y, Qin X. Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus. Ann Clin Microbiol Antimicrob. 2018 Feb 20;17(1):5. doi: 10.1186/s12941-018-0257-x. PMID: 29463249; PMCID: PMC5819674.
  15. Bremmer DN, Balada-Llasat JM, Goff DA, Bauer KA. Ceftriaxone Etest non-susceptible methicillin susceptible Staphylococcus aureus time-kill responses. Diagn Microbiol Infect Dis. 2017 Jun;88(2):192-194. doi: 10.1016/j.diagmicrobio.2017.02.019. Epub 2017 Mar 2. PMID: 28291629.
  16. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010 May;54(5):1670-7. doi: 10.1128/AAC.00019-10. Epub 2010 Mar 1. PMID: 20194704; PMCID: PMC2863635.
  17. Palmer SM, Kang SL, Cappelletty DM, Rybak MJ. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 1995 Aug;39(8):1764-71. doi: 10.1128/AAC.39.8.1764. PMID: 7486916; PMCID: PMC162823.
  18. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89-96. doi: 10.1016/0732-8893(95)00053-d. PMID: 7587056.
  19. Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, Perrotin D, Dequin PF, Le Guellec C. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol. 2011 Nov;72(5):758-67. doi: 10.1111/j.1365-2125.2011.04005.x. PMID: 21545483; PMCID: PMC3243010.
  20. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001 Apr;47(4):421-9. doi: 10.1093/jac/47.4.421. PMID: 11266414.
  21. Van Wart SA et al., ICAAC 2009, poster # A1-010
  22. Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014 Sep;44(3):235-41. doi: 10.1016/j.ijantimicag.2014.05.012. Epub 2014 Jun 24. PMID: 25052866.
  23. Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. J Antimicrob Chemother. 2018 Jul 1;73(7):1888-1894. doi: 10.1093/jac/dky120. PMID: 29635472.
  24. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, Leibovici L, Bishara J. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect. 2011 Oct;17(10):1581-6. doi: 10.1111/j.1469-0691.2010.03425.x. Epub 2010 Dec 14. PMID: 21073629.
  25. Carr DR, Stiefel U, Bonomo RA, Burant CJ, Sims SV. A Comparison of Cefazolin Versus Ceftriaxone for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia in a Tertiary Care VA Medical Center. Open Forum Infect Dis. 2018 May 18;5(5):ofy089. doi: 10.1093/ofid/ofy089. PMID: 30568987; PMCID: PMC5961173.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#56 – Empiric Escalation: Gazing into the Crystal Ball for Multidrug-Resistant Gram-Negatives

Drs. Kate DeSear (@IDPharmD_Kate) and Frank Tverdek (@FTverdek) join Dr. Julie Ann Justo (@julie_justo) to discuss the practice of empiric escalation in this episode of our gram-negative resistance series. Listen in for encouragement on following your intuition and tips on how, when, and why to practice this other side of antimicrobial stewardship.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

#55 – One World: Global Perspectives in Antimicrobial Stewardship

Drs. Debbie Goff (@idpharmd), Khalid Eljaaly (@khalideljaaly), and Angeliki Messina (@AngPharmID) join Dr. David Ha (@DHpharmd) as part of a global panel discussion on international antimicrobial stewardship practices. Listen in to learn about pharmacy practice in South Africa and Saudi Arabia, antimicrobial stewardship practices in these and other countries, and how you too can get involved in global stewardship.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

  • 2022 ACCP Global Conference on Clinical Pharmacy. https://www.accp.com/meetings/abstracts.aspx
  • Alhazzani W, Alshahrani M, Alshamsi F, Aljuhani O, Eljaaly K, Hashim S, et al. The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. J Infect Public Health. 2022;15(1):142-151. doi:10.1016/j.jiph.2021.10.005.
  • Brink AJ, Messina AP, Feldman C, et al. Antimicrobial stewardship across 47 South African hospitals: an implementation study. Lancet Infect Dis. 2016;16(9):1017-1025. doi:10.1016/S1473-3099(16)30012-3
  • Goff DA, Ashiru‐Oredope D, Cairns KA, et al. Global contributions of pharmacists during the COVID‐19 pandemic. J Am Coll Clin Pharm. Published online October 2, 2020:10.1002/jac5.1329. doi:10.1002/jac5.1329
  • Eljaaly K, Elarabi S, Alshehri S, Nix DE. Impact of requiring re-authorization of restricted antibiotics on day three of therapy. J Antimicrob Chemother 2018;73(2):527-530. doi:10.1093/jac/dkx384.
  • Korayem GB, Badreldin HA, Eljaaly K, et al. Clinical pharmacy definition, required education, training and practice in Saudi Arabia: A position statement by the Saudi society of clinical pharmacy. Saudi Pharm J. 2021;29(11):1343-1347. doi:10.1016/j.jsps.2021.09.008.
  • International Pharmaceutical Federation Development Goals: Antimicrobial Stewardship. https://developmentgoals.fip.org/dg17/
  • Messina AP, van den Bergh D, Goff DA. Antimicrobial Stewardship with Pharmacist Intervention Improves Timeliness of Antimicrobials Across Thirty-three Hospitals in South Africa. Infect Dis Ther. 2015;4(Suppl 1):5-14. doi:10.1007/s40121-015-0082-x
  • Open Access BSAC eBook "Antimicrobial Stewardship: From Principles to Practice". https://www.bsac.org.uk/antimicrobialstewardshipebook/BSAC-AntimicrobialStewardship-FromPrinciplestoPractice-eBook.pdf
  • Open Access BSAC course "Antimicrobial Stewardship for the Gulf, Middle East and North Africa". https://www.futurelearn.com/courses/antimicrobial-stewardship-for-the-middle-east
  • Saudi Society of Clinical Pharmacy Infectious Disease Pharmacy Specialty Network. https://sscp.org.sa/infectious-disease/
  • World Health Organization. Antimicrobial Stewardship Programmes in Health-Care Facilities in Low- and Middle-Income Countries: A WHO Practical Toolkit. World Health Organization; 2019. Accessed March 9, 2022. http://apps.who.int/iris/handle/10665/329404

#54 – Connecting with our Colleagues: COVID-19 Treatments in Community Pharmacies

Dr. Jennifer Morrow joins Dr. Rachel Britt (@RachelBPharmD) on this bonus episode of the Breakpoints podcast to discuss how the introduction of COVID-19 therapeutics and vaccines has affected community pharmacy teams and workflows. Also mentioned are the recent Test to Treat initiative, impacts on future community pharmacy practice, and ways inpatient providers can help our community colleagues.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References:

#53 – Abscessus and fortuitum and avium, Oh My!: Updates and Controversies in NTM Management

Drs. Wendi Drummond and Jeff Pearson (@jeffpears0n) join Dr. Rachel Britt (@RachelBPharmD) on the Breakpoints podcast this week to discuss all things on non-tuberculosis mycobacteria pulmonary infections. Listen for answers to all your burning questions like “Are we still using IV amikacin?” and “How do I get omadacycline for my patient?” as well as learning why clofazimine is the coolest drug out there. For more NTM content, check out Dr. Drummond’s podcast, NTMTalk!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References:

  1. www.doi.org/10.1093/cid/ciaa241 
  2. www.doi.org/10.1164/rccm.200604-571ST 
  3. www.doi.org/10.1136/thoraxjnl-2015-207360 
  4. www.doi.org/10.1136/thoraxjnl-2017-210927 
  5. www.doi.org/10.1093/ofid/ofaa415 
  6. www.doi.org/10.1093/ofid/ofab002
  7. https://clinicaltrials.gov/ct2/show/NCT04922554

#52 – A Conversation with the Authors of IDSA Guidance on Treatment of AmpC, CRAB, and Stenotrophomonas

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd) are BACK on the podcast this week with Dr. Erin McCreary (@ErinMcCreary) to discuss IDSA guidance on AmpC producers, carbapenem-resistant Acinetobacter baumanii, and Stenotrophomonas as part of our series on gram-negative bacteria. Listen as the panelists navigate the hot mess that is the CRAB treatment landscape, have a minocycline appreciation moment (we stan for Steno Sam!), and throw down some bar trivia in an "I Feel Nerdy" segment that you don't want to miss.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

  1. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) - PubMed (nih.gov)
  2. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections - PubMed (nih.gov)
  3. An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria
  4. Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy

#51 – A Conversation with the Authors of IDSA Guidance on Treatment of ESBL, CRE, and DTR Pseudomonas